Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aquestive Therapeutics, Inc. Director's Dealing 2019

Mar 4, 2019

32552_dirs_2019-03-04_8983bcfb-adc6-4267-baf1-3699c59a6138.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aquestive Therapeutics, Inc. (AQST)
CIK: 0001398733
Period of Report: 2019-02-28

Reporting Person: Boyd Peter E. (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-02-28 Non-Qualified Stock Option (right to buy) $8.05 A 30000 Acquired 2029-02-28 Common Stock (30000) Direct

Footnotes

F1: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries.